Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are scheduled to receive a type of preparatory chemotherapy (called lymphodepleting chemotherapy) before a commercially available CAR-T cell therapy, for the treatment of multiple myeloma, leukemia, or lymphoma
- People whose bone marrow is functioning well enough to receive the preparatory chemotherapy
- People whose kidneys are not working at full capacity, specifically with a kidney function measurement at or below 60mL/min/1.73m² (confirm with trial site)
- People with a general health and activity level rated between 0 and 2 on a standard medical scale, meaning they are fully active or able to carry out light work but may have some limitations
Who may not be able to join:
- People who have certain disorders affecting the brain or central nervous system (confirm with trial site for specific conditions that apply)
- People who have an active infection that is not under control, or any other ongoing illness or medical condition that the trial doctor believes could interfere with the study
- People who have been taking higher-dose steroid medications (such as prednisone at more than 20mg per day, or an equivalent steroid) within the 72 hours before their CAR-T cell therapy is given
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 404-255-1930
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of CRS; Occurrence of ICANS; Occurrence of Cytopenias
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.